



# Supplementary figure 1



Supplementary figure 1 | gating strategy for selecting CD3+ T cells from DC-CIK cells

## Supplementary Figure 2



**Supplementary figure 2 | Annexin V-APC/7-AAD apoptosis assay and cell viability assay with CCK8 kit. a** The apoptosis rates of CD3+T cells from DC-CIK cells which were treated with mock (PBS), ERK inhibitor (100 nM/L), AKT inhibitor (1.0 µM/L) or pembrolizumab (500 µg/ml) for 48h. **b** Statistical histogram of (a). **c, d, e** the viability of DC-CIK cells when treated with different concentrations of ERK inhibitor (0, 50, 100, 150 nM/L) (**c**), AKT inhibitor (0, 250, 500, 1000 nM/L) (**d**) or pembrolizumab (0, 125, 250, 500 µg/ml) (**e**) for 72h. Representative results from three independent experiments are shown. “ns” indicated as no statistical significance.